Mk 0752

Manufactured by Selleck Chemicals

Sourced in United States

The MK-0752 is a laboratory instrument designed for the precise measurement and analysis of various chemical and physical properties. It features advanced sensor technology and customizable software to facilitate accurate data collection and processing. The core function of the MK-0752 is to provide reliable and reproducible results for research and development applications.

Automatically generated - may contain errors

Lab products found in correlation

8 protocols using mk 0752

Combination Therapy for Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

cetuximab (Merck Serono; Lot no. 143886), trastuzumab (Roche; Lot no. B3435B01) and Notch inhibitor, (MK0752, Selleck; Lot no. S266001) for this study were procured and prepared appropriately.

Brijwani N., Jain M., Dhandapani M., Zahed F., Mukhopadhyay P., Biswas M., Khatri D., Radhakrishna V.D., Majumder B., Radhakrishnan P, & Thiyagarajan S. (2017). Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Scientific Reports, 7, 1502.

+ Open protocol

+ Expand

MK-0752 Treatment of Zebrafish Embryos

Check if the same lab product or an alternative is used in the 5 most similar protocols

Working solutions were prepared from 10 mM MK-0752 (Selleckchem) stock solution and 100% DMSO (Invitrogen) in 1x E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl₂, 0.33 mM MgSO₄). Embryos (20 embryos/mL) were incubated with 100 μM MK-0752 or 1% DMSO from bud to 17 or 20 hpf at 28.5°C, followed by 1x E3 medium washes and maintenance at 28.5°C. Embryos were maintained until 24 hpf, at which point they were fixed with 4% paraformaldehyde (PFA) in 1x PBS at 4°C overnight. Embryos were also incubated with 100 μM MK-0752 or 1% DMSO from bud to 24 hpf at 28.5°C before fixation. Embryos were incubated with 50 μM MK-0752 or 0.5% DMSO from bud to 13 or 14 hpf, or from 11 to 14 or 15 hpf, followed by 1x E3 medium washes and maintained at 28.5°C until 24 hpf stage for fixation. Embryos were also incubated with 75 μM MK-0752 or 0.75% DMSO from bud to 15, 16 or 17 hpf, or from 12 to 17 hpf at 28.5°C, followed by 1x E3 medium washes; embryos were maintained at 28.5°C until fixation at the 24 hpf stage.

Lu Y.F., Liu D.W., Li I.C., Lin J., Wang C.M., Chu K.C., Kuo H.H., Lin C.Y., Yih L.H., Jiang Y.J, & Hwang S.P. (2021). Delta/Jagged-mediated Notch signaling induces the differentiation of agr2-positive epidermal mucous cells in zebrafish embryos. PLoS Genetics, 17(12), e1009969.

+ Open protocol

+ Expand

Antibody Sources for HCV Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were obtained: anti-HCV NS5A mouse monoclonal antibody (5A27)15 (link), anti-HCV core mouse monoclonal antibody (Fujirebio, Japan), anti-actin mouse monoclonal antibody (Sigma, A2228), anti-HA rat monoclonal antibody (Roche, clone 3F10), anti-GFP mouse monoclonal antibody (Clontech, JL-8), anti-E1 mouse monoclonal antibody (toru0726cb-1)51 (link), anti-E6AP antibody (Sigma), anti-PA28γ antibody52 (link), anti-p62 antibody (MBL) and horseradish peroxidase-conjugated anti-FLAG mouse monoclonal antibody (Sigma, clone M2). Anti-SPP rabbit polyclonal antibody was generated by immunization with synthetic peptides from amino acids 356 to 366 of mouse SPP (YEESNPKDPAA). LY-411575, ALLN (A6185), MG132, and bafilomycin A1 (B1793) were obtained from Sigma. RO4929097, avagacestat, semagacestat, DAPT (GSI-IX), and MK-0752 were purchased from Selleck Chemicals. Epoxomicin (4381-v), lactacystin (4368-v), E-64d (4321-v), and pepstatin A (4397-v) were from Peptide Institute, Inc.

Aizawa S., Okamoto T., Sugiyama Y., Kouwaki T., Ito A., Suzuki T., Ono C., Fukuhara T., Yamamoto M., Okochi M., Hiraga N., Imamura M., Chayama K., Suzuki R., Shoji I., Moriishi K., Moriya K., Koike K, & Matsuura Y. (2016). TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis. Nature Communications, 7, 11379.

+ Open protocol

+ Expand

Synergistic Effects of GSI-1 and AR Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

To evaluate the combined effect of the GSI-1 and the AR inhibitors, cells were grown in recommended media containing 10% FBS for 48 hours. After 48 hours at confluency of 50% cells were then treated with the indicated concentrations of the drugs (0, 1, 5, or 10μM), either alone or in combination at the indicated time points. Initially other γ-secretase inhibitors including DAPT, MK-0752, Semagacestat, and R04929097 (all from Selleckchem, Houston, TX) were also evaluated for the synergistic effect with the AR inhibitors but only GSI-1 show significant synergy with AR inhibitors and selected for further evaluation.

Mohamed A.A., Tan S.H., Xavier C.P., Katta S., Huang W., Ravindranath L., Jamal M., Li H., Srivastava M., Srivatsan E., Sreenath T., McLeod D.G., Srinivasan A., Petrovics G., Dobi A, & Srivastava S. (2017). Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-positive Prostate Cancer Cells. Molecular cancer research : MCR, 15(10), 1308-1317.

+ Open protocol

+ Expand

Investigating Combination Therapies in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Curcumin (S1848), lapatinib (S2111), brigatinib (S8229), MK-0752 (S2660), sapitinib (S2192), and WP1066 (S2796) were all purchased from SellekChem. Cobimetinib (HY-13064), selumetinib (HY-50706), alpelisib (HY-15244), and trametinib (HY-10999) were purchased from MedChemExpress. Rapamycin (SC3504A) was acquired from SantaCruz Biotechnology and curcuplex-95 from Xymogen.

Allaf A., Victoria B., Rosario R., Misztal C., Humayun Gultekin S., Dinh C.T, & Fernandez-Valle C. (2022). WP1066 induces cell death in a schwannomatosis patient–derived schwannoma cell line. Cold Spring Harbor Molecular Case Studies, 8(4), a006178.

+ Open protocol

+ Expand

Modulating Notch Signaling in MM-MGEC Interaction

Check if the same lab product or an alternative is used in the 5 most similar protocols

MMECs were transiently transfected with control siRNAs, Jagged1∙siRNA 25 nM, Jagged2∙siRNA 25 nM, Notch1·siRNA 25 nM, Notch2·siRNA 50 nM (SMART-pool; Dharmacon RNA Technologies, Lafayette, CO), or the transfection reagent alone (Lipofectamine, RNAiMAX siRNA transfection reagent, Invitrogen Corp.) for 72 hours. For co-culture experiments, MM cells were added the day after the treatment. MM cells were transiently transfected with control siRNAs, Jagged1∙siRNA 25 nM, Jagged2∙siRNA 25 nM, or the transfection reagent alone for 48 hours.
MMECs cultured alone or co-cultured with RPMI-8226 cells with/without transwell were treated with vehicle or MK-0752 (Selleckchem, Houston, TX) 5 nM for 48 hours.

Saltarella I., Frassanito M.A., Lamanuzzi A., Brevi A., Leone P., Desantis V., Di Marzo L., Bellone M., Derudas D., Ribatti D., Chiaramonte R., Palano M.T., Neri A., Mariggiò M.A., Fumarulo R., Dammacco F., Racanelli V., Vacca A, & Ria R. (2018). Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?. Neoplasia (New York, N.Y.), 21(1), 93-105.

+ Open protocol

+ Expand

Cytotoxic Drug Screening Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

The drugs, TG-101209, NVP-TAE684, MK-0752, actinomycin-d, and panobinostat were purchased from Selleckchem (S2692, S1108, S2660, S8964, S1030, Selleckchem, Houston, TX, USA), and withaferin-a was purchased from Sigma (W4394, Sigma-Aldrich, Saint Louis, MO, USA). These drugs were dissolved in DMSO. The cells were seeded in a 96-well plate at 20×10³ cells per well. Day after seeding, drugs were added to the wells at a proper concentration, TG-101209 (6nM), NVP-TAE684 (3nM), MK-0752 (5nM), withaferin-a (4uM), actinomycin-d (0.3nM), and panobinostat (5nM) and treated for one day. The cells in the negative control group were only treated by DMSO for one day.

Li X., Shong K., Kim W., Yuan M., Yang H., Sato Y., Kume H., Ogawa S., Turkez H., Shoaie S., Boren J., Nielsen J., Uhlen M., Zhang C, & Mardinoglu A. (2022). Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach. EBioMedicine, 78, 103963.

+ Open protocol

+ Expand

Compound Acquisition and Antibody Sources

Check if the same lab product or an alternative is used in the 5 most similar protocols

Semagacestat was purchased from two different sources (Selleck and Santa Cruz Biotechnology). RO4929097, MK-0752, and avagacestat were purchased from Selleck. Antibodies used for biochemical analysis and their respective sources are as follows: anti-bAPP (22C11; Millipore); anti-PS1 (anti-PS1 loop domain ; Calbiochem); anti-PS2 (Cell Signaling Technology); anti-pan-Ab (4G8; Covance); anti-Ab N terminus (82E1; IBL); anti-Ab40 C terminus (18580; IBL); anti-Ab43 C terminus (18583; IBL); anti-b-actin (AC-15; Sigma); horseradish peroxidase (HRP)-labeled anti-rabbit immunoglobulin G (IgG) (Promega); and HRP-labeled anti-mouse IgG (Promega). Antibodies used for immunocytochemistry were anti-b-III TUBULIN (Covance) and anti-NESTIN (Covance), and the secondary antibodies were anti-mouse-Alexa488 (Life Technologies) and anti-rabbit-Alexa555 (Cell Signal). Antiserum (OB1195) against the C terminus of NICASTRIN (amino acids 693-709) conjugated to keyhole limpet hemocyanin (KLH) was raised by the method described previously (Fukumori et al., 2006) . Antiserum 6618 against the C terminus of bAPP has been described previously (Fukumori et al., 2006) .

Tagami S., Yanagida K., Kodama T.S., Takami M., Mizuta N., Oyama H., Nishitomi K., Chiu Y.W., Okamoto T., Ikeuchi T., Sakaguchi G., Kudo T., Matsuura Y., Fukumori A., Takeda M., Ihara Y, & Okochi M. (2017). Semagacestat Is a Pseudo-Inhibitor of γ-Secretase. Cell reports, 21(1).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!